A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.
Mrinal M GounderTodd M BauerGary K SchwartzAmy M WeisePatricia LoRussoPrasanna KumarBen TaoYing HongParul PatelYasong LuArnaud LesegretainVijaya G TirunagaruFeng XuRobert C DoebeleDavid S HongPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
An intermittent dosing schedule of 3/14 days of milademetan mitigates dose-limiting hematologic abnormalities while maintaining efficacy. Notable single-agent activity with milademetan in dedifferentiated liposarcomas has prompted a randomized phase III trial (MANTRA).